Literature DB >> 8915800

Pharmacotherapy of photorefractive keratectomy.

S A Arshinoff1, M D Mills, S Haber.   

Abstract

PURPOSE: To compare the pharmacotherapeutic practices of high-volume photorefractive keratectomy (PRK) surgeons with suggested practices gleaned from the current literature.
SETTING: York Finch Eye Associates, Toronto, Canada.
METHODS: Seventy-five ophthalmic surgeons believed by the authors to do a high-volume of PRKs were surveyed over the summer of 1994 about their pharmacotherapeutic practices. The results were compared with suggested practices extracted from a review of the current literature.
RESULTS: Relatively consistent approaches to the management of post-PRK pain and prevention of acute post-PRK subepithelial infiltrative keratitis were reported. The administration of topical steroids after PRK was almost universally employed. Post-PRK analgesia was most commonly achieved with nonsteroidal anti-inflammatory drugs (NSAIDs) and a soft contact lens, but surgeons were not convinced of the benefits of long-term NSAID administration to control myopic regression and haze. There seemed to be no agreed-on solution to the infrequent problems of severe haze and regression and steroid-induced elevated intraocular pressure after PRK; however, many useful suggestions for the management of these problems were proposed.
CONCLUSION: In general, high-volume PRK surgeons use topical steroids, NSAIDs, and a soft contact lens in the immediate postoperative period, although they are uncertain about the long-term effectiveness of NSAIDs in controlling regression and haze.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915800     DOI: 10.1016/s0886-3350(96)80116-7

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  8 in total

1.  Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00% versus cyclosporine A 0.05%.

Authors:  Chyong Jy Nien; Kevin J Flynn; Melissa Chang; Donald Brown; James V Jester
Journal:  J Cataract Refract Surg       Date:  2011-03-15       Impact factor: 3.351

2.  Reversal of fibrosis by TGF-β3 in a 3D in vitro model.

Authors:  D Karamichos; A E K Hutcheon; J D Zieske
Journal:  Exp Eye Res       Date:  2014-05-04       Impact factor: 3.467

3.  Optical effects of anti-TGFbeta treatment after photorefractive keratectomy in a cat model.

Authors:  Jens Bühren; Lana Nagy; Jennifer N Swanton; Shawn Kenner; Scott MacRae; Richard P Phipps; Krystel R Huxlin
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

4.  Effect of Homatropine eye drops on pain after photorefractive keratectomy: A pilot study.

Authors:  Mahmoud Joshaghani; Hossein Nazari; Khalil Ghasemi Falavarjani; Siamak Shokrollahi; Mohammad Jafar Ghaempanah; Kaveh Abri Aghdam; Zahra Mirbolouk Jalali
Journal:  Saudi J Ophthalmol       Date:  2012-07-31

5.  The incidence of central serous chorioretinopathy after photorefractive keratectomy and laser in situ keratomileusis.

Authors:  Majid Moshirfar; Maylon Hsu; Julia Schulman; Joseph Armenia; Shameema Sikder; M Elizabeth Hartnett
Journal:  J Ophthalmol       Date:  2012-02-12       Impact factor: 1.909

6.  Comparison of the effect of cycloplegic versus NSAID eye drops on pain after photorefractive keratectomy.

Authors:  Kaveh Abri Aghdam; Hossein Aghaei; Siamak Shokrollahi; Mahmoud Joshaghani; Hossein Nazari; Masih Hashemi; Mohammad Jafar Ghaempanah
Journal:  J Curr Ophthalmol       Date:  2016-01-08

Review 7.  Preferred practice patterns for photorefractive keratectomy surgery.

Authors:  Rajesh Fogla; Gaurav Luthra; Aishwarya Chhabra; Krati Gupta; Ritika Dalal; Pooja Khamar
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

8.  Topical rosiglitazone is an effective anti-scarring agent in the cornea.

Authors:  Krystel R Huxlin; Holly B Hindman; Kye-Im Jeon; Jens Bühren; Scott MacRae; Margaret DeMagistris; David Ciufo; Patricia J Sime; Richard P Phipps
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.